在慢性自发性疹中对奥马利祖马布的反应的预测因素:一个回顾性队列研究
Özge Zorlu1, Hülya Albayrak1, Sema Aytekin1
1Department of Dermatology and Venereology, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey.
Cutaneous and ocular toxicology
|October 8, 2025
概括
在慢性自发性疹症 (CSU) 中预测奥马利祖马布的反应至关重要. 基线白细胞 (WBC) 和淋巴细胞计数,以及血小板指数,显示了一些预测价值,但它们的临床效用是有限的.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 奥马利祖马布对慢性自发性疹 (CSU) 有效.
- 患者对奥马利祖马布的反应时间因患者而异.
- 确定对奥马利祖马布反应的预测生物标志物对于个性化治疗至关重要.
研究的目的:
- 评估基线血液学和炎症性参数作为CSU患者对奥马利祖马布反应的预测指标.
- 评估患者特异性特征及其在预测治疗疗效方面的作用.
- 为了研究早期与晚期对标准剂量奥马利祖马布治疗的反应.
主要方法:
- 一项对242名CSU患者进行的回顾性队列研究,这些患者接受了奥马利祖马布治疗 (300毫克每4周).
- 评估人口统计,临床特征和基线实验室测试.
- 根据疹活动评分 (UAS7) 将患者分为早期响应者 (ER),晚期响应者 (LR) 和非响应者 (NR).
主要成果:
- 早期响应者 (ERs) 的白细胞 (WBC) 和淋巴细胞数量较高,平均血小板体积/淋巴细胞比率 (MPVLR) 更低.
- 晚反应者 (LRs) 的体质血红蛋白度 (MCHC) 和血小板/淋巴细胞比率 (PLR) 高,血小板平均体积 (MPV) 较低.
- 红细胞分布宽度变化系数 (RDW-CV),WBC计数和血小板分布宽度 (PDW) 预测了整体反应,而淋巴细胞计数,MPVLR,MCHC和PLR预测了早期或晚期反应,尽管预测力有限.
结论:
- 基线血液学参数,如白细胞计数,淋巴细胞计数,RDW-CV,PDW,MPVLR,MCHC和PLR,为CSU中的奥马利祖马布反应提供了一些见解.
- 然而,这些参数单独显示出有限的预测能力.
- 需要进一步的研究来确定更强大的生物标志物来预测CSU管理中的奥马利祖马布疗效.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Allergic Reactions
32.0K
Overview
32.0K
Hypersensitivities
7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K


